Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine.

Trial Profile

Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Pertussis acellular vaccine (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Pneumococcal 11-valent vaccine conjugate; RIX 4414
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Pharmacodynamics
  • Acronyms PA-TRICOMP005
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Feb 2011 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top